Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients

Immunocore Holdings Plc IMCR announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid tumors.

• IMC-C103C was developed using the Company's ImmTAC technology platform and is being developed in partnership with Genentech, a member of Roche Holdings AG RHHBY.
• IMC-C103C demonstrated a manageable safety profile. The most common treatment-related adverse events were cytokine release syndrome and were dose-dependent and rapidly resolved. 
• The most common severe adverse event was neutropenia, typically at doses over 90 micrograms. 
• None of the treatment-related AEs led to discontinuation or death.
• Data showed biomarkers of T cell activation consistent and robust at doses over 90 micrograms.
• One ovarian cancer patient, with a very low MAGE protein expression, treated at a dose of less 90 micrograms, had a durable confirmed partial response (PR) with 8.3 months duration. 
• An additional ovarian cancer patient at a dose of over 90 micrograms, with very low MAGE-A4 protein expression, has a confirmed partial response ongoing at 4.4+ months. 
• One of the three non-ovarian cancer patients (head and neck squamous cell carcinoma) at a dose of over 90 micrograms has a confirmed PR that is ongoing.
• Immunocore initiated an expansion arm in high-grade serous ovarian carcinoma at 140 micrograms. 
• The Company plans to present additional data from this program in 2022. 
• Price Action: IMCR shares are down 5.96% at $27 during the market session on the last check Monday.